Dose Determination of Cinacalcet Hydrochloride in Japanese Hemodialysis Patients With Secondary Hyperparathyroidism
Authors:
- Takashi AkibaTATakashi Akiba
- KRN1493 Study GroupKGKRN1493 Study Group
- 2 April 2008
- journal article
- research article
- Published by Wiley in Therapeutic Apheresis and Dialysis
- Vol. 12 (2) , 117-125
Abstract
Abstract: Cinacalcet hydrochloride is a calcimimetic agent that activates the calcium‐sensing receptor on the surface of parathyroid cells and inhibits parathyroid hormone (PTH) secretion. To manage secondary hyperparathyroidism, cinacalcet, which lowers PTH levels without increasing serum calcium, phosphorus and calcium–phosphorus product (Ca × P) levels, may provide a new potential therapy. To identify the optimal starting dose of cinacalcet for Japanese hemodialysis patients with secondary hyperparathyroidism, this double‐blind, placebo‐controlled, parallel, dose‐finding study was conducted. One hundred and twenty Japanese hemodialysis patients with intact PTH levels greater than or equal to 300 pg/mL were randomized into four groups: placebo, and 12.5, 25 and 50 mg of cinacalcet. The treatment period was three weeks followed by a two‐week follow‐up observation period. Cinacalcet decreased serum intact PTH levels in a dose‐dependent manner, and also decreased serum calcium, phosphorus, Ca × P, tartrate‐resistant acid phosphatase and osteocalcin levels. The treatment with cinacalcet was generally well tolerated in this study. However, the incidence of treatment‐related adverse events, such as gastrointestinal disorders and hypocalcemia, and the rate of withdrawal from the study due to treatment‐related adverse events were higher in the 50 mg dose group than in the other groups. On the basis of both efficacy and safety results, 25 mg has been identified as the optimal starting dose of cinacalcet for Japanese hemodialysis patients with secondary hyperparathyroidism.Keywords
This publication has 18 references indexed in Scilit:
- Predictors and consequences of altered mineral metabolism: The Dialysis Outcomes and Practice Patterns StudyKidney International, 2005
- Cinacalcet HCl, an Oral Calcimimetic Agent for the Treatment of Secondary Hyperparathyroidism in Hemodialysis and Peritoneal DialysisJournal of the American Society of Nephrology, 2005
- Magnitude and impact of abnormal mineral metabolism in hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS)American Journal of Kidney Diseases, 2004
- Mineral Metabolism, Mortality, and Morbidity in Maintenance HemodialysisJournal of the American Society of Nephrology, 2004
- The calcimimetic AMG 073 reduces parathyroid hormone and calcium x phosphorus in secondary hyperparathyroidismKidney International, 2003
- Arterial Calcifications, Arterial Stiffness, and Cardiovascular Risk in End-Stage Renal DiseaseHypertension, 2001
- Recent developments in the management of secondary hyperparathyroidismKidney International, 2001
- Coronary-Artery Calcification in Young Adults with End-Stage Renal Disease Who Are Undergoing DialysisNew England Journal of Medicine, 2000
- Pathogenesis of secondary hyperparathyroidismKidney International, 1999
- Intravenous Calcitriol in the Treatment of Refractory Osteitis Fibrosa of Chronic Renal FailureNew England Journal of Medicine, 1989